Uretheroileal suspension technique during radical cystectomy
Outcomes of Uretheroileal Suspension Technique During Open Radical Cystectomy and Ileal Neobladder: A Prospective Randomized Comparative Study
This study is testing a new surgical technique during bladder cancer surgery to see if it helps patients recover better than the usual methods.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Trial ID | NCT06783855 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the outcomes of a uretheroileal suspension technique used during open radical cystectomy for patients with muscle-invasive and certain non-muscle-invasive bladder cancers. The procedure involves ligating and dividing the puboprostatic ligaments and dorsal vein complex, followed by the reconstruction of an ileal pouch. The study aims to assess the effectiveness of this technique compared to conventional methods in terms of surgical outcomes and recovery. Participants will undergo a detailed surgical process that includes specific suturing techniques to ensure proper anastomosis.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with muscle-invasive bladder carcinoma or specific cases of non-muscle-invasive bladder carcinoma that are unresponsive to other treatments.
Not a fit: Patients with benign bladder conditions, severe renal dysfunction, or poor overall health status may not benefit from this study.
Why it matters
Potential benefit: If successful, this technique could improve surgical outcomes and recovery for patients undergoing radical cystectomy.
How similar studies have performed: While this approach is innovative, similar surgical techniques have shown promise in improving outcomes in bladder cancer surgeries.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient age \>18 years. * Muscle-invasive bladder carcinoma (MIBC). * Non-muscle-invasive bladder carcinoma (NMIBC) fulfilling the following criteria: 1. \- (recurrent disease that is unresponsive to other treatments 2. \- high-grade tumors (T1, carcinoma in situ) refractory to intravesical therapy 3. -Multifocal or recurrent high-grade tumors despite intravesical therapy and the tumor progression from NMIBC to MIBC). Exclusion Criteria: * NMIBC or benign disease. * Severe hepatic renal dysfunction. * Urethral involvement with bladder carcinoma. * Poor overall health status. * Severe renal dysfunction.
Where this trial is running
Sohag
- Sohag University Hospital — Sohag, Egypt (Recruiting)
Study contacts
- Study coordinator: abdelrahman m abdellah, assistant lecturer
- Email: abdelrahman.ahmed1@med.shag.edu.eg
- Phone: +201014649841
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.